- Role will help further advance revolutionary blood-based technology
IRVING, Texas, March 5, 2013 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, announced today that it has named Joachim Schorr, PhD, as its Chief Scientific Officer. He joins Caris in this role after working as a consultant with the company during the past year. In this expanded capacity, Dr. Schorr's extensive expertise in the molecular sciences arena will help to shape and advance Caris' research and development strategy.
"Having worked closely with Caris Life Sciences in 2012 as Senior Scientific Advisor, I have seen firsthand the world-class work being done every day at Caris to advance innovation in the field of personalized medicine," said Dr. Schorr. "Given our position as the emerging standard for cancer tumor profiling with the Molecular Intelligence Service, I am convinced that Caris is set to transform cancer diagnosis and patient care through its blood-based Carisome platform. I am excited to be part of this scientific paradigm shift."
Before joining Caris, Dr. Schorr held various leadership positions at QIAGEN N.V., the global leader in sample and assay Technologies, until April 2012. In his most recent role there, he served as Senior Vice President Global R&D and Managing Director, was a member of the Executive Committee and was responsible for research and development activities worldwide. In addition to his expanded role as CSO for Caris, Dr. Schorr will continue to serve as a scientific consultant for QIAGEN.
During his 20-year career at QIAGEN, Dr. Schorr led the development of a global R&D function that created many new breakthrough products for use in life sciences research as well as molecular diagnostics. He also played a critical role in the successful integration of new technologies and products into the QIAGEN portfolio. In addition, he played key roles in the integrations of acquired companies, including Genovison, Operon, Artus, DxS, Digene and DxAssays.
Prior to joining QIAGEN, Dr. Schorr worked at Hoechst, the German chemical-pharmaceuticals company, and was involved in the development of an oral malaria vaccine that received the IHK research award in 1991. He was also co-founder of Coley Pharmaceuticals, EnPharma Pharmaceuticals, and QBM Cell Sciences. Dr. Schorr holds a Ph.D. in Molecular Biology and Virology from the University of Cologne.
"The value that Joachim brings to Caris through his extensive scientific and business experiences in the industry as well as his key strategic insights have been clearly evident to our organization over this past year," said David D. Halbert, Chairman and Chief Executive Officer of Caris Life Sciences. "In his official capacity as Chief Scientific Officer, we look forward to Joachim making significant contributions to further advance our innovative technology platforms – platforms that will fundamentally change the way medicine is practiced. We are very pleased to officially welcome him to the Caris Life Sciences team."
About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of personalized medicine. Caris' Molecular Intelligence™ Service (MI Profile™) correlates molecular data generated from a patient's tumor with biomarker/drug associations derived from the world's leading clinical cancer literature. This service uses the most advanced and clinically-relevant technologies to provide physicians with information to aid in the selection of personalized cancer treatments more likely to work for each patient. Caris is also developing a series of blood tests based on the company's proprietary Carisome® platform — a blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in the Dallas metroplex, Caris Life Sciences offers services throughout the United States, Europe, and other international markets. To learn more, please visit www.carislifesciences.com.
SOURCE Caris Life Sciences